Zoetis Inc (ZTS) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket
 


Zoetis Inc   (NYSE: ZTS)


Zoetis Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Zoetis Inc's ROI in the third quarter of 2026?
Zoetis Inc achieved a return on average invested assets (ROI) of 18.85 % in its third quarter of 2026, this is above ZTS's average return on investment of 15.33%.
Zoetis Inc s investments during the 12 months ending in the third quarter of 2026 are valued at $13 billion

ROI decreased relative to the period ending Jun 30 2026, due to the decline in net income.

Within the Healthcare sector 60 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 309, from total ROI ranking in the second quarter of 2026 at 321.

Definition and Formula of Return on Investment



Return On Investment (Sep 30 2026)
III. Quarter
(Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 13.15 % 17.62 % 11.26 % 3.28 % -7.17 %
Y / Y Net Income Change TTM -5.48 % 0.58 % 41.39 % 108.33 % 280.06 %
Investment (TTM) in Millions 12,406 13,016 13,101 14,221 13,497
Return On Investment (TTM) 18.85 % 19.44 % 20.35 % 21.24 % 22.57 %
ZTS's Overall Ranking # 309 # 321 # 126 # 259 #
Seq. Investment Change TTM -2.03 % 3.3 % 4.36 % 7.13 % 1.84 %
Seq. Net Income Change TTM -4.97 % -1.32 % -0.04 % 0.84 % 1.11 %
Net Income (TTM) in Millions 2,486 2,616 2,651 2,652 2,630




Return On Investment ZTS's Ranking
Within: No.
Industry # 29
Sector # 61
Overall # 309

Return On Investment Statistics
High Average Low
22.37 %
15.33 %
6.18 %
(Jun 30 2025)  



  News about Zoetis Inc Return on Investment ROI

Zoetis Announces Third Quarter 2024 Results

November 4, 2024

Zoetis Inc.: A Beacon of Growth in Animal Health and Commitment to DiversityAs the global landscape of animal health continues to evolve, Zoetis Inc. (NYSE: ZTS) has been at the forefront, exhibiting remarkable financial growth and an unwavering commitment to Diversity, Equity, and Inclusion (DEandI). With significant strides made in the third quarter of 2024, alongside recognition for its inclusive corporate culture, Zoetis showcases a dual commitment to both economic performance and social responsibility that sets it apart in the animal health industry. Financial Performance Overview In recent announcements, Zoetis reported impressive financial results for the third quarter of 2024. The company achieved revenues of $2.4 billion, marking an 11% increase compared to the same period in the previous year. On an operational basis, the revenue rose even more significantly, with a reported 14% increase year-over-year. This robust financial performance is indicative of Zoetis’ effective strategies in expanding its product offerings and market presence.






Financial Statements
Zoetis Inc's III. Quarter Investments $ 12,406 Millions ZTS's Balance sheet
Zoetis Inc's III. Quarter Income $ 591 Millions Quarterly ZTS's Income Statement
ZTS's Income by Division See ZTS's Income by Division


ZTS Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 13,232 10,825 12,391 11,756 12,104
Y / Y Investment Growth 22.24 % -12.64 % 5.4 % -2.88 % 5.78 %
Net Income in Millions 2,673 2,496 2,340 2,111 2,034
Y / Y Net Income Growth 7.09 % 6.67 % 10.85 % 3.79 % 24.33 %
Annual Return On Investment 20.2 % 23.06 % 18.88 % 17.96 % 16.8 %


Annual Roi Comment
In the fiscal year 2025 ROI deteriorated to 20.2 %, despite net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ZTS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ZTS's Competitors
Subscribers only: Roi for Zoetis Inc's Suppliers
Subscribers only: Return On Investment for ZTS's Customers

Other Ratios
ZTS's Roa ZTS's Inventory Turnover Ratio ZTS's Growth Rates ZTS's Dividend Statistics
ZTS's Profitability Ratios ZTS's Asset Turnover Ratio ZTS's Dividend Growth
ZTS's Roe ZTS's Valuation Ratios ZTS's Financial Strength Ratios ZTS's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Standard Biotools Inc   23.91 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %
Amgen Inc   13.64 %
Carlisle Companies Incorporated  13.64 %
Bristol myers Squibb Company  13.59 %


Date modified: 2026-11-06T12:59:59+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.